In conclusion, long-term administration of GPR55 agonist Abn-CBD and GPR119 agonist AS-1269574 improved glycaemic control in a multiple-low-dose STZ-induced mouse model of diabetes, resulting in decreased plasma glucose and glucagon and improved plasma insulin, GLP-1 and lipid profiles. The gene discussed is GCG; the disease is diabetes mellitus.